Should I buy or sell Genenta Science stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNTA shares. View GNTA analyst ratings or view top-rated stocks .

What is Genenta Science's stock price target for 2024?

3 brokerages have issued 1-year target prices for Genenta Science's shares. Their GNTA share price targets range from $15.00 to $25.00. On average, they expect the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 281.7% from the stock's current price. View analysts price targets for GNTA or view top-rated stocks among Wall Street analysts .

How have GNTA shares performed in 2023?

Genenta Science's stock was trading at $5.50 at the beginning of the year. Since then, GNTA stock has decreased by 4.7% and is now trading at $5.24. View the best growth stocks for 2023 here .

Are investors shorting Genenta Science?

Genenta Science saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,400 shares, an increase of 37.0% from the October 31st total of 5,400 shares. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is currently 3.9 days. View Genenta Science's Short Interest .

When did Genenta Science IPO?

(GNTA) raised $28 million in an initial public offering (IPO) on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Genenta Science Stock Price, News & Analysis (NASDAQ:GNTA)

$5.24

+0.04 (+0.77%)

(As of 09:30 AM ET)

Compare

Today's Range: $5.24
▼
$5.24
50-Day Range: $4.70
▼
$5.80
52-Week Range: $4.29
▼
$7.08

Volume: 1,026 shs
Average Volume: 2,842 shs
Market Capitalization: $95.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

Genenta Science MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 281.7% Upside
$20.00 Price Target
Short Interest: Healthy
0.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.56) to ($0.93) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

661st out of 949 stocks

Biological Products, Except Diagnostic Industry

110th out of 164 stocks

3.5

Analyst's Opinion

Consensus Rating
Genenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, Genenta Science has a forecasted upside of 281.7% from its current price of $5.24.
Amount of Analyst Coverage
Genenta Science has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.04% of the outstanding shares of Genenta Science have been sold short.
Short Interest Ratio / Days to Cover
Genenta Science has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genenta Science has recently increased by 37.04%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Genenta Science does not currently pay a dividend.
Dividend Growth
Genenta Science does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GNTA.

2.4

News and Social Media Coverage

News Sentiment
Genenta Science has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Genenta Science this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for GNTA on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genenta Science insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.52% of the stock of Genenta Science is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Genenta Science are expected to decrease in the coming year, from ($0.56) to ($0.93) per share.
Price to Book Value per Share Ratio
Genenta Science has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genenta Science Stock (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNTA Stock News Headlines

November 24, 2023 | americanbankingnews.com

Critical Review: Tenaya Therapeutics (NASDAQ:TNYA) versus Genenta Science (NASDAQ:GNTA)

November 14, 2023 | finance.yahoo.com

Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

August 18, 2023 | au.finance.yahoo.com

Genenta Science S.p.A. (GNTA)

July 28, 2023 | finance.yahoo.com

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

July 8, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation

June 29, 2023 | finanznachrichten.de

GENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma

June 29, 2023 | finance.yahoo.com

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

May 17, 2023 | finance.yahoo.com

Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company

May 16, 2023 | finance.yahoo.com

Genenta to Provide Update on Lead Product Temferon™

April 26, 2023 | finanznachrichten.de

GENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

April 26, 2023 | finance.yahoo.com

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

April 3, 2023 | finance.yahoo.com

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

March 2, 2023 | marketwatch.com

Genenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTA

March 2, 2023 | finance.yahoo.com

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

February 24, 2023 | wsj.com

Genenta Science S.p.A. ADR

February 8, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)

February 7, 2023 | finance.yahoo.com

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

January 29, 2023 | finance.yahoo.com

We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth

December 8, 2022 | finance.yahoo.com

Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%

November 7, 2022 | finance.yahoo.com

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

October 24, 2022 | finance.yahoo.com

Genenta Provides First Half 2022 Business Update and Financial Results

October 5, 2022 | finance.yahoo.com

Genenta to Present at Upcoming Scientific and Investor Conferences

September 7, 2022 | finance.yahoo.com

Genenta to Present at Upcoming Investor Conferences

August 22, 2022 | finance.yahoo.com

We're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Rate

July 27, 2022 | uk.investing.com

This Small Cap Cancer Company 'Hijacks Tumors From Within," HC Wainwright Says

See More Headlines

Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNTA
CUSIP: N/A
CIK: 1838716
Web: www.genenta.com
Phone: 39-02-2643-4681
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.00
High Stock Price Target: $25.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +304.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.84
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 2.75

Miscellaneous

Outstanding Shares: 18,217,000
Free Float: 12,936,000
Market Cap: $90.17 million
Optionable: Not Optionable
Beta: 0.91

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Pierluigi Paracchi (Age 50)
Vice Chairman of the Board, CEO & GM
Dr. Luigi Naldini M.D. (Age 64)
Ph.D., Co-Founder & Chairman of the Executive Scientific Board
Dr. Bernard Rudolph Gentner M.D. (Age 48)
Ph.D., Co-Founder & Member of the Executive Scientific Board
Mr. Richard B. Slansky (Age 65)
Chief Financial Officer
Dr. Carlo Russo M.D. (Age 70)
Chief Medical Officer & Head of Development
Dr. Stefania Mazzoleni Ph.D. (Age 41)
Director of Program Development
Ms. Barbara Regonini
Director of Finance

Key Competitors

View All Competitors

GNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Genenta Science stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNTA shares.
View GNTA analyst ratings or view top-rated stocks.
What is Genenta Science's stock price target for 2024?: 3 brokerages have issued 1-year target prices for Genenta Science's shares. Their GNTA share price targets range from $15.00 to $25.00. On average, they expect the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 281.7% from the stock's current price.
View analysts price targets for GNTA or view top-rated stocks among Wall Street analysts.
How have GNTA shares performed in 2023?: Genenta Science's stock was trading at $5.50 at the beginning of the year. Since then, GNTA stock has decreased by 4.7% and is now trading at $5.24.
View the best growth stocks for 2023 here.
Are investors shorting Genenta Science?: Genenta Science saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,400 shares, an increase of 37.0% from the October 31st total of 5,400 shares. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is currently 3.9 days.
View Genenta Science's Short Interest.

When did Genenta Science IPO?: (GNTA) raised $28 million in an initial public offering (IPO) on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.
How do I buy shares of Genenta Science?: Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNTA) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial